BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30175777)

  • 1. Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study.
    Hakamata J; Kaneko Y; Shimizu M; Yamaoka K; Maruyama J; Takeuchi T; Mochizuki M; Hashiguchi M
    Biol Pharm Bull; 2018; 41(9):1414-1422. PubMed ID: 30175777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
    Hayashi H; Tazoe Y; Tsuboi S; Horino M; Morishita M; Arai T; Ohshima M; Matsuyama T; Kosuge K; Yamada H; Tsuji D; Inoue K; Itoh K
    Drug Metab Pharmacokinet; 2013; 28(2):164-8. PubMed ID: 22971639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
    Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
    Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population.
    Lv S; Fan H; Yang H; Huang J; Li J; Shu X; Zhang L; Xu Y; Li X; Zuo J; Lv C; Kong X; Xiao C
    J Clin Pharmacol; 2019 Nov; 59(11):1471-1476. PubMed ID: 31099054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.
    Hakamata J; Hashiguchi M; Kaneko Y; Yamaoka K; Shimizu M; Maruyama J; Takeuchi T; Mochizuki M
    Mod Rheumatol; 2018 Jul; 28(4):611-620. PubMed ID: 29252093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
    Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
    Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.
    Świerkot J; Ślęzak R; Karpiński P; Pawłowska J; Noga L; Szechiński J; Wiland P
    Pol Arch Med Wewn; 2015; 125(3):152-61. PubMed ID: 25599563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies.
    Kung TN; Dennis J; Ma Y; Xie G; Bykerk V; Pope J; Thorne C; Keystone E; Siminovitch KA; Gagnon F
    Arthritis Rheumatol; 2014 May; 66(5):1111-20. PubMed ID: 24782176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.
    Muralidharan N; Mariaselvam CM; Mithun CB; Negi VS
    Clin Rheumatol; 2016 Apr; 35(4):879-85. PubMed ID: 25771854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients.
    Lima A; Bernardes M; Sousa H; Azevedo R; Costa L; Ventura F; Seabra V; Medeiros R
    Pharmacogenomics; 2014 Apr; 15(6):807-20. PubMed ID: 24350725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis.
    Hayashi H; Fujimaki C; Daimon T; Tsuboi S; Matsuyama T; Itoh K
    J Clin Pharm Ther; 2009 Jun; 34(3):355-61. PubMed ID: 19827168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
    van der Straaten RJ; Wessels JA; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Allaart CF; Bogaartz J; Tiller M; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2007 Feb; 8(2):141-50. PubMed ID: 17286537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis.
    Ghodke-Puranik Y; Puranik AS; Shintre P; Joshi K; Patwardhan B; Lamba J; Niewold TB; Chopra A
    Pharmacogenomics; 2015 Dec; 16(18):2019-34. PubMed ID: 26616421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis.
    Dervieux T; Kremer J; Lein DO; Capps R; Barham R; Meyer G; Smith K; Caldwell J; Furst DE
    Pharmacogenetics; 2004 Nov; 14(11):733-9. PubMed ID: 15564880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of genes involved in methotrexate pathway: Predictors of response to methotrexate therapy in Indian rheumatoid arthritis patients.
    Singh A; Gangadharan H; Gupta V; Patro PS; Misra R; Aggarwal A
    Int J Rheum Dis; 2021 May; 24(5):654-662. PubMed ID: 33780152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients.
    Jekic B; Lukovic L; Bunjevacki V; Milic V; Novakovic I; Damnjanovic T; Milasin J; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Kovacevic L; Krajinovic M
    Eur J Clin Pharmacol; 2013 Mar; 69(3):377-83. PubMed ID: 22763757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients.
    Sandhu A; Ahmad S; Kaur J; Bhatnagar A; Dhawan V; Dhir V
    Clin Rheumatol; 2018 Dec; 37(12):3221-3228. PubMed ID: 30022368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue.
    Stamp LK; Hazlett J; Highton J; Hessian PA
    J Rheumatol; 2013 Sep; 40(9):1519-22. PubMed ID: 23858048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.